In addition, other preclinical experiments have shown that the combination of STING agonists (such as ADU-S100) with HER2-targeted drugs (such as trastuzumab or DS-8201) can significantly reduce the proportion of cancer stem cells and inhibit the clonogenic ability of drug-resistant cells, suggesting that STING activation may reverse resistance by remodeling the TME and regulating stem cell properties (75). This evidence concerns the gene ERBB2 and cancer.